Streetbeat News

Products Services

INTC

MBLY

Intel has announced that it currently has no plans to divest a majority interest in Mobileye, reaffirming its belief in the future of autonomous driving technology.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 11:53 am

BABA

BIDU

JD

LI

NIO

NVDA

PDD

XPEV

ZK

Chinese tech stocks, including Alibaba, PDD, JD.com, and Baidu, are rising following a U.S. Federal Reserve interest rate cut. This move is expected to boost discretionary spending and aid Chinese companies investing in AI technology. Chinese EV stocks like NIO, XPeng, and Li Auto are also up. Alibaba's cloud unit will host the Aspara Conference 2024, focusing on AI advancements.

Portfolio Pulse from Anusuya Lahiri

September 19, 2024 | 11:38 am

DCGO

DocGo is expanding its program to improve healthcare access for Medi-Cal enrollees in California. The initiative targets underserved communities in several counties through a partnership with a major national insurance provider.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 11:37 am

BTAI

Bioxcel Therapeutics is shifting its focus from sales efforts for its approved drug Igalmi to clinical prioritization. The company will keep Igalmi on the market but without its current commercial infrastructure.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 11:31 am

LRMR

Larimar Therapeutics will present data from its Nomlabofusp Phase 1 and Phase 2 studies at the Annual International Congress for Ataxia Research. Some of this data has been previously disclosed.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 11:29 am

GLMD

Galmed Pharmaceuticals is expanding its drug development with two new programs targeting cancer and cardiac fibrosis. The company plans to release new data in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 11:25 am

SYTA

Siyata Mobile has announced that its SD7 handsets and VK7 vehicle kits have been purchased and deployed by Trans-west Security Systems, marking a new customer acquisition.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 11:23 am

ACET

Adicet Bio released promising clinical biomarker data from its Phase 1 GLEAN trial for ADI-001, an allogeneic cell therapy targeting autoimmune diseases. The data showed effective tissue trafficking, CAR T cell activation, and CD19+ B cell depletion.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 11:21 am

TLSA

Tiziana Life Sciences has received a $4 million grant from the National Institutes of Health to study nasal anti-CD3 for Alzheimer's disease. This funding will support preclinical and clinical studies, potentially advancing treatment options for the condition.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 11:20 am

ONCY

Oncolytics Biotech reported positive clinical results from the BRACELET-1 study, showing improved overall survival and response rates for its breast cancer treatment combining pelareorep with paclitaxel.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 11:19 am